Statements (109)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:monoclonal_antibody
|
| gptkbp:administered_by |
gptkb:healthcare_professionals
subcutaneous injection |
| gptkbp:affects |
lipid metabolism
|
| gptkbp:approves |
gptkb:2015
gptkb:European_Union gptkb:FDA gptkb:United_States |
| gptkbp:available_in |
pre-filled syringes
autoinjectors |
| gptkbp:brand |
gptkb:Repatha
|
| gptkbp:can_be_combined_with |
other lipid-lowering therapies
|
| gptkbp:can_be_used_with |
gptkb:ezetimibe
niacin fibrates |
| gptkbp:can_cause |
fatigue
headache muscle pain |
| gptkbp:chemical_formula |
C4056 H6230 N1064 O1260 S44
|
| gptkbp:class |
lipid-lowering agent
|
| gptkbp:clinical_trial |
gptkb:DESCARTES_trial
gptkb:FOURIER_trial gptkb:LAPLACE-2_trial Phase 3 Phase III EVOLVE trial ODYSSEY trial |
| gptkbp:clinical_use |
gptkb:familial_hypercholesterolemia
primary hyperlipidemia |
| gptkbp:competitors |
gptkb:Alirocumab
Lomitapide Mipomersen |
| gptkbp:contraindication |
hypersensitivity to the drug
|
| gptkbp:developed_by |
gptkb:Amgen
|
| gptkbp:dosage_form |
solution for injection
75 mg or 140 mg |
| gptkbp:financial_stability |
stable until expiration date
|
| gptkbp:financial_support |
Repatha Patient Support Program
|
| gptkbp:formulation |
auto-injector
pre-filled syringe |
| gptkbp:frequency |
once every two weeks
|
| gptkbp:has_impact_on |
triglyceride levels
|
| https://www.w3.org/2000/01/rdf-schema#label |
Evolocumab
|
| gptkbp:indication |
patients with cardiovascular disease
hyperlipidemia cardiovascular risk reduction |
| gptkbp:interacts_with |
other lipid-lowering therapies
|
| gptkbp:invention |
patented
|
| gptkbp:investment |
heart attack
stroke cardiovascular events |
| gptkbp:is |
a first-line therapy
a statin |
| gptkbp:is_a_guide_for |
AHA/ ACC guidelines
ESC/ EAS guidelines |
| gptkbp:is_compared_to |
statins
|
| gptkbp:is_considered |
a second-line treatment
effective in lowering cholesterol |
| gptkbp:is_evaluated_by |
clinical studies
long-term efficacy long-term safety |
| gptkbp:is_linked_to |
reduced LDL levels
|
| gptkbp:is_monitored_by |
allergic reactions
|
| gptkbp:is_part_of |
cholesterol management
lipid-lowering therapy regimen |
| gptkbp:is_recommended_for |
patients with high cholesterol
|
| gptkbp:is_studied_in |
gptkb:familial_hypercholesterolemia
high-risk patients non-familial hyperlipidemia |
| gptkbp:is_subject_to |
insurance coverage
|
| gptkbp:is_used_in |
preventive cardiology
primary prevention secondary prevention |
| gptkbp:lifespan |
11 to 17 days
|
| gptkbp:marketed_as |
gptkb:Repatha
gptkb:2015 |
| gptkbp:mechanism_of_action |
inhibits PCSK9 protein
PCSK9 inhibition |
| gptkbp:patient_population |
adults
children over 12 years |
| gptkbp:price |
high
|
| gptkbp:reduces |
LDL cholesterol levels
|
| gptkbp:regulatory_compliance |
FDA approved
EMA approved |
| gptkbp:requires |
patient education
|
| gptkbp:research_areas |
gptkb:biotechnology
cardiology pharmacology |
| gptkbp:route_of_administration |
subcutaneous
self-administered by patients |
| gptkbp:service_frequency |
once every 2 weeks or once a month
|
| gptkbp:should_be_administered |
after warming to room temperature
|
| gptkbp:should_be_stored_at |
refrigerated temperatures
|
| gptkbp:should_not_be_frozen |
gptkb:true
|
| gptkbp:showed |
improve cardiovascular outcomes
|
| gptkbp:side_effect |
muscle pain
allergic reactions injection site reactions nasopharyngitis myalgia |
| gptkbp:storage |
refrigerated
|
| gptkbp:suitable_for |
pregnant women
severe liver disease |
| gptkbp:targets |
gptkb:PCSK9
|
| gptkbp:used_for |
hyperlipidemia
lowering LDL cholesterol |
| gptkbp:weight |
144.2 k Da
|
| gptkbp:bfsParent |
gptkb:PCSK9_inhibitors
|
| gptkbp:bfsLayer |
7
|